Powles, T, Brown, J, Larkin, J et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534
Metadata
Authors/Creators: |
|
---|---|
Keywords: | Renal cell carcinoma, tyrosine kinase inhibitor, biomarker, SRC, VEGF |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 05 Dec 2018 15:17 |
Last Modified: | 05 Dec 2018 15:17 |
Status: | Published |
Publisher: | Oxford University Press |
Identification Number: | https://doi.org/10.1093/annonc/mdw014 |
Related URLs: |
Download not available
A full text copy of this item is not currently available from White Rose Research Online